ERBC is a leading independent Contract Research Organization in Europe specialized in non-clinical studies, from preclinical proof-of-concept to market, in line with the current international regulatory requirements.
Comprehensive development of all products
We offer GLP and non GLP studies together with NHP breeding to pharmaceutical, biotech, chemical, food, veterinairan and medical industries, worldwide.
History
Step by step
a Group
Since November 2019, ERBC is building the leading independent non-clinical CRO in Europe, through:
The acquisition of talents,
The development of expertise,
Internal development of capacities/models
M&A and strategic partnerships
Nov 2019
ERBC creation
Following the acquisition of RTC (Italy) by CERB, >50 years of experience in preclinical regulatory development of drugs & chemicals
Dec 2020
Acquisition of BIOPRIM
Acquisition of BIOPRIM Baziège, 31, for securing NHP supply
Jul 2022
Acquisition of NOVAXIA
Acquisition of NOVAXIA St Laurent-Nouan, 41 for solidifying histopathology expertise
Dec 2022
Acquisition of ONCOFACTORY
Acquisition of ONCOFACTORY, Lyon, 69, for selecting anticancer drugs and patients for the clinic
Jul 2023
Acquisition of VOXCAN
Acquisition of VOXCAN, Dommartin, 69, for imaging and biosafety confinement laboratories (BSL2 &3)
Location
Locations
ERBC is currently organized around
6 sites in Europe. Click on each location (point) to access more details.
ERBC Blois
Pathology Hub
ERBC Baugy
General toxicology, Safety Pharmacology, Pharmacology
Cynomolgus, dogs, and laboratories marmosets & rodents
ERBC Dommartin
Discovery and high-resolution in vivo imaging
Oncology, virology, medical imaging Rodents, rabbit, ferret
ERBC Lyon
Discovery, Clinical & Translational Research in Oncology
Oncology, immuno-oncology PDX models
ERBC Toulouse
Breeding & Quarantine Unit
Cynomolgus, marmosets, aethiops
ERBC Pomezia
Pomezia, Italy (nearby Roma) General toxicology, DART/juvenile, Genetic/ In vitro tox.
Minipigs, rodents
Team
Board management
At ERBC, our Board and Management Team is composed of experienced leaders committed to driving innovation and excellence in preclinical research and regulatory toxicology. With deep expertise in science, business strategy, and regulatory frameworks, our leadership team ensures that ERBC remains a trusted partner for the pharmaceutical, chemical, agrochemical, cosmetic, and medical device industries.
At ERBC, we understand the importance of responsibility in every step of our processes. As part of our ongoing commitment to Animal Welfare and Ethics, we adhere to the core principles of Replacement, Reduction, and Refinement (3Rs) and integrate Responsibility and Rehoming, as 4th and 5th Rs, to ensure animal well-being in our everyday approach to advancing science.
At ERBC, we are committed to providing the highest quality preclinical and clinical research services. We follow regulatory standards and use a Total Quality Approach to create a unified, simple, strong, and integrated quality management system across all ERBC sites and activities. Our transformation is guided by a risk-based approach, improving our predictive capabilities, agility, and efficiency.
At ERBC, we are committed to sustainable development and corporate responsibility. Our CSR strategy is focused on three key pillars: Social Responsibility, Environmental Stewardship, and Governance Excellence. These pillars guide our actions and drive positive impact for our employees, clients, suppliers, and the environment. Our goal is to integrate sustainability into everything we do, ensuring a healthier future for generations to come.